- Home
- JBGS vs DVAX Comparison
JBGS vs DVAX Comparison
Compare JBGS & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBGS
- DVAX
- Stock Information
- Founded
- JBGS 2016
- DVAX 1996
- Country
- JBGS United States
- DVAX United States
- Employees
- JBGS N/A
- DVAX N/A
- Industry
- JBGS Real Estate Investment Trusts
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- JBGS Real Estate
- DVAX Health Care
- Exchange
- JBGS Nasdaq
- DVAX Nasdaq
- Market Cap
- JBGS 1.4B
- DVAX 1.7B
- IPO Year
- JBGS 2017
- DVAX 2004
- Fundamental
- Price
- JBGS $15.36
- DVAX $12.82
- Analyst Decision
- JBGS Sell
- DVAX Buy
- Analyst Count
- JBGS 2
- DVAX 2
- Target Price
- JBGS $16.00
- DVAX $22.00
- AVG Volume (30 Days)
- JBGS 719.7K
- DVAX 1.6M
- Earning Date
- JBGS 02-18-2025
- DVAX 02-20-2025
- Dividend Yield
- JBGS 4.56%
- DVAX N/A
- EPS Growth
- JBGS N/A
- DVAX N/A
- EPS
- JBGS N/A
- DVAX 0.15
- Revenue
- JBGS $567,034,000.00
- DVAX $260,810,000.00
- Revenue This Year
- JBGS N/A
- DVAX $21.64
- Revenue Next Year
- JBGS N/A
- DVAX $19.81
- P/E Ratio
- JBGS N/A
- DVAX $84.17
- Revenue Growth
- JBGS N/A
- DVAX N/A
- 52 Week Low
- JBGS $13.65
- DVAX $9.74
- 52 Week High
- JBGS $18.86
- DVAX $15.01
- Technical
- Relative Strength Index (RSI)
- JBGS 36.93
- DVAX 54.61
- Support Level
- JBGS $15.13
- DVAX $12.54
- Resistance Level
- JBGS $16.93
- DVAX $13.02
- Average True Range (ATR)
- JBGS 0.45
- DVAX 0.31
- MACD
- JBGS -0.09
- DVAX -0.05
- Stochastic Oscillator
- JBGS 12.08
- DVAX 42.86
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in and develops real estate assets concentrated in urban infill submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to the legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily and third-party asset management and real estate services. The company generates majority of its revenue from Commercial segment.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.